Despite reporting lower revenues in the first half of the year, Formycon continues to see value in its biosimilar projects, with a new candidate to be launched in the second half of 2024.
“Formycon can look back on a very successful first half of the year, characterized by significant progress in its development projects,” commented Formycon’s CEO Stefan Glombitza on the firm's financial results for the first half of 2024.
The star of the first half of the year is Cimerli, a biosimilar rival to Genentech’s Lucentis (ranibizumab), as its...
Video provides a powerful way to help you prove your point. When you click Online Video, you can paste in the embed code for the video you want to add. You can also type a keyword to search online for the video that best fits your document.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
